✦ LIBER ✦

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

✍ Scribed by Thomas Bachelot; Gilles Romieu; Mario Campone; Véronique Diéras; Claire Cropet; Florence Dalenc; Marta Jimenez; Emilie Le Rhun; Jean-Yves Pierga; Anthony Gonçalves; Marianne Leheurteur; Julien Domont; Maya Gutierrez; Hervé Curé; Jean-Marc Ferrero; Catherine Labbe-Devilliers

Book ID: 119609059
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 267 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70432-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of lapatinib p

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

✍ Nancy U. Lin; Wolfgang Eierman; Richard Greil; Mario Campone; Bella Kaufman; Kla 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 189 KB

Multicenter Phase II Study of Lapatinib

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

✍ Lin, N. U.; Dieras, V.; Paul, D.; Lossignol, D.; Christodoulou, C.; Stemmler, H. 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 368 KB

Multicenter Phase II Study of Lapatinib

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

✍ Lin, N. U.; Dieras, V.; Paul, D.; Lossignol, D.; Christodoulou, C.; Stemmler, H. 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 368 KB

5077 Lapatinib plus letrozole vs. letroz

5077 Lapatinib plus letrozole vs. letrozole alone in patients (pts) with endocrine sensitive, HER2+, previously untreated metastatic breast cancer (MBC) with multiple (>3sites) or liver metastases

✍ X. Pivot; J. Maltzman; L. O'Rourke; A. Florance; S. Johnston 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Treatment of HER2-positive metastatic br

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience

✍ Sutherland, S; Ashley, S; Miles, D; Chan, S; Wardley, A; Davidson, N; Bhatti, R; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 450 KB

A phase I study of lapatinib with whole

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

✍ Lin, Nancy U.; Freedman, Rachel A.; Ramakrishna, Naren; Younger, Jerry; Storniol 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 241 KB